The California NanoSystems Institute (CNSI) at UCLA has announced a partnership with the global biopharmaceutical company Abraxis BioScience to collaborate on nanobiotechnology research to develop new technologies in medicine.
Abraxis has agreed to contribute $10m over 10 years to fund collaborative projects at UCLA’s new CNSI building. The new research laboratory will focus on quickly translating scientific discoveries into practical applications.
By joining the CNSI Partners Program, Abraxis and CNSI will be able to jointly research ways to diagnose and treat life-threatening diseases.
‘Nanosystems research is breaking down the barriers between disciplines to achieve a seamless integration between chemistry, physics, biology and engineering in all of their different forms,’ said Fraser Stoddart, CNSI director and UCLA’s Fred Kavli professor of nanosystems sciences.